Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Spekulatius who wrote (14284)	4/9/2002 1:42:15 AM
From: Paul Senior	Read Replies (4) \| Respond to of 78740

re PCOP (and AGN). At first glance PCOP looks a little too tough for me to analyze and/or bet on. OT(?): Speculatius (or anyone else): What's your opinion on Allergan? I wonder if the stock will recover given the apparently enormous (?) interest in, or popularity (?) of, Botox. Or is the "Botox phenomenon" already built into the stock price? Here, not only am I ignorant of the potential drug pipeline and business prospects for AGN, but also I've been clueless until now as regards this latest thing in wrinkle-remover/cosmetic enhancements that apparently is so very well known on both coasts. And if what I read is correct, "the effect normally lasts three months...for treatments that average $400", there could be recurring income. (Although $1600/yr to remove wrinkles seems like a limited market to me, bwdik.) finance.yahoo.com